PT Prodia Widyahusada TbkPRWDF 69 EV-to-EBITDA is 0.00 as of Jul. 08, 2026. GuruFocus rates PRWDF with a GF Score™ of 69/100. The stock has 2 warning signs investors should review. Among 118 Medical Diagnostics & Research companies, PT Prodia Widyahusada Tbk ranks better than 92.37% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PT Prodia Widyahusada Tbk's enterprise value is $0.00 Mil.
PT Prodia Widyahusada Tbk's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $28.78 Mil. Therefore, PT Prodia Widyahusada Tbk's EV-to-EBITDA for today is 0.00.
The historical rank and industry rank for PT Prodia Widyahusada Tbk's EV-to-EBITDA or its related term are showing as below:
PRWDF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.82 Med: 6.43 Max: 81.6
Current: 3.1
During the past 13 years, the highest EV-to-EBITDA of PT Prodia Widyahusada Tbk was 81.60. The lowest was 2.82. And the median was 6.43.
PRWDF's EV-to-EBITDA is ranked better than 92.37% of 118
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.99
vs PRWDF: 3.10
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PT Prodia Widyahusada Tbk's PE Ratio (TTM) for today is calculated as:
PT Prodia Widyahusada Tbk's share price for today is $0.00.
PT Prodia Widyahusada Tbk's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, PT Prodia Widyahusada Tbk's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Prodia Widyahusada Tbk EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PT Prodia Widyahusada Tbk's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Prodia Widyahusada Tbk's EV-to-EBITDA falls into.
PT Prodia Widyahusada Tbk's current Enterprise Value is $0.00 Mil.
PT Prodia Widyahusada Tbk's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $28.78 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Prodia Widyahusada Tbk (PRWDF) has a EV-to-EBITDA of 0.00 as of Jul. 08, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Prodia Widyahusada Tbk. Over the past decade, PT Prodia Widyahusada Tbk's EV-to-EBITDA has ranged from 2.82 to 81.60. According to the industry distribution chart, PT Prodia Widyahusada Tbk ranks #9 out of 118 companies in the Medical Diagnostics & Research industry, placing it in the top 7.6%.
Is PT Prodia Widyahusada Tbk's EV-to-EBITDA too high?
PT Prodia Widyahusada Tbk's current EV-to-EBITDA is 0.00. Over the past 10 years, this metric has ranged from a low of 2.82 to a high of 81.60. Based on the distribution chart, PT Prodia Widyahusada Tbk ranks #9 out of 118 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, PT Prodia Widyahusada Tbk has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does PT Prodia Widyahusada Tbk's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PT Prodia Widyahusada Tbk ranks #9 out of 118 companies for EV-to-EBITDA. This places PT Prodia Widyahusada Tbk in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.99. Historically, PT Prodia Widyahusada Tbk's own EV-to-EBITDA has ranged from 2.82 to 81.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.99, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Prodia Widyahusada Tbk. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Prodia Widyahusada Tbk's current EV-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Prodia Widyahusada Tbk stock overvalued right now?
PT Prodia Widyahusada Tbk (PRWDF) has a current EV-to-EBITDA of 0.00. The current EV-to-EBITDA is 0.00. PT Prodia Widyahusada Tbk's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PT Prodia Widyahusada Tbk (PRWDF), the current EV-to-EBITDA is 0.00 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PT Prodia Widyahusada Tbk provides health care testing services. The company provides analytic and diagnostic services for the medical professionals. It is engaged in health laboratories by conducting business activities such as setting up clinics, health laboratories, management of hospitals, and health checkup services. Its operating segments are Central: Jakarta; Sumatera: Sumatera, Kepulauan Riau; Greater Jakarta: Jakarta, Bogor, Depok, Tangerang, Bekasi, Lampung, Pangkal Pinang; West Java; Central Java; East Java, Bali, Nusa Tenggara; Kalimantan Sulampua: Kalimantan, Sulawesi, Ambon, Papua.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PRWDF has been successfully added to your 